COGNITION THERAPEUTICS INC — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cognition Therapeutics achieved FDA alignment on primary/secondary endpoints for a Phase 3 registrational trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and received a patent on a novel crystalline form expiring 2045. Q3 2026 net loss was $4.1M ($0.04/share) on R&D spending of $5.1M; the company holds $31.5M cash plus $18.2M in obligated NIH grant funds, estimated sufficient through Q4 2027. Phase 2 START study results in Alzheimer's disease expected H2 2027.
Why this rating
Phase 3 FDA alignment is material milestone for clinical-stage biotech; 1.7x cash relative to market cap extends runway; patent protection to 2045 is favorable. Event is significant but not transformational—execution risk remains high.
Tradability signal
NO TRADE
No trade: positive news with only +1.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=365). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.69 | +10 min · unknown $0.68 ▼ 0.78% | +30 min · unknown $0.66 ▼ 4.35% | +1 hr · unknown $0.66 ▼ 4.91% | +4 hrs · unknown $0.64 ▼ 7.16% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.